Animal vs Human Peptide Research

A large majority of the ‘evidence’ cited in online peptide content is rodent or other animal data. This page explains why translation to humans is the exception, not the rule.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Translational failure is the default

Across drug development as a whole, the great majority of compounds that show effect in animal models never reach human use. The translational failure rate is high not because animal studies are badly done, but because species differ in receptor distribution, immunogenicity, pharmacokinetics, and the relevance of the disease model used.

Dose extrapolation is unreliable

Allometric (body-surface-area) scaling is a starting point used in first-in-human studies — not a finished answer. For peptides, dose extrapolation is further complicated by route-of-administration effects (sc / im / oral), enzymatic degradation, and species-specific binding affinity at receptors.

Species differences that matter

• Receptor density and subtype distribution.
• Plasma half-life and clearance pathways.
• Immune response — rodents may not produce neutralising antibodies that humans would.
• Disease model relevance — a chemically-induced rat model often does not match human pathophysiology.

Publication bias

Positive findings are more likely to be published. A single positive rodent paper appears to readers as “the evidence” while null replication attempts may sit unpublished. Apparent strength of a preclinical literature is partly an artefact of which studies got through.

What this means in practice

On PeptideStacks, claims supported only by animal evidence receive a Grade C (or lower) by default. A compound with a strong preclinical record but no human trial data is not, on our methodology, considered established for any human use. See: evidence grading methodology.